Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Data integration with Fusion Searchlight: Classifying brain states from resting-state fMRI.

NeuroImage·2025
Same author

Neurosteroids and translocator protein 18 kDa (TSPO) ligands as novel treatment options in depression.

European archives of psychiatry and clinical neuroscience·2024
Same author

Local and global effects of sedation in resting-state fMRI: a randomized, placebo-controlled comparison between etifoxine and alprazolam.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2024
Same author

The translocator protein 18kDa ligand etifoxine in the treatment of depressive disorders-a double-blind, randomized, placebo-controlled proof-of-concept study.

Trials·2024
Same author

Medical cannabis and 'Total Pain' in a cancer population.

BMJ supportive & palliative care·2024
Same author

Inhalation-modulated detection of olfactory BOLD responses in the human brain.

Frontiers in neuroimaging·2023
Same journal

Cancer Patients with Neuropathic Pain: Pharmacist-Led Recommendation and Management and Mirogabalin Outcomes in a Single-Center Retrospective Observational Cohort.

Journal of pain & palliative care pharmacotherapy·2026
Same journal

Cost-Effectiveness of Integrative Pain Management for Chronic Pain: A Systematic Review of Economic Evaluation.

Journal of pain & palliative care pharmacotherapy·2026
Same journal

High-Dose Monotherapy or Combination Therapy in Neuropathic Pain: A Necessary Reflection.

Journal of pain & palliative care pharmacotherapy·2026
Same journal

The Price of Goodbye.

Journal of pain & palliative care pharmacotherapy·2026
Same journal

In the End, What Shall We Say?

Journal of pain & palliative care pharmacotherapy·2026
Same journal

The Use of Ketamine for Depression in Cancer Patients: A Systematic Review of Efficacy, Safety, and Clinical Applications.

Journal of pain & palliative care pharmacotherapy·2026
See all related articles

Related Experiment Video

Updated: May 16, 2026

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
03:50

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Published on: August 18, 2023

Opioid-induced constipation.

Simon Wein1

  • 1Pain and Palliative Care Service, Davidoff Center, Rabin Medical Center, Petach Tikvah, Israel. simonwe@clalit.org.il

Journal of Pain & Palliative Care Pharmacotherapy
|December 11, 2012
PubMed
Summary
This summary is machine-generated.

Opioid-induced constipation (OIC) is a common side effect of opioid pain relievers. This review covers OIC features, mechanisms, and management strategies, including laxatives and specific antagonists.

Related Experiment Videos

Last Updated: May 16, 2026

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
03:50

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Published on: August 18, 2023

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Opioid medications are widely prescribed for pain management.
  • Opioid-induced constipation (OIC) is a frequent and distressing adverse effect.
  • OIC significantly impacts patient quality of life and treatment adherence.

Purpose of the Study:

  • To provide a comprehensive overview of opioid-induced constipation.
  • To discuss the underlying mechanisms of OIC.
  • To review current and emerging management strategies for OIC.

Main Methods:

  • Literature review of opioid-induced constipation.
  • Analysis of the pathophysiology of OIC.
  • Evaluation of pharmacological interventions for OIC.

Main Results:

  • Opioid agonists activate μ-opioid receptors in the gastrointestinal tract, slowing motility.
  • Management involves lifestyle modifications, various classes of laxatives (osmotic, stimulant, stool softeners), and suppositories.
  • Peripherally acting μ-opioid receptor antagonists show promise in mitigating OIC without affecting central analgesia.

Conclusions:

  • Opioid-induced constipation is a complex condition requiring multifaceted management.
  • Laxative therapy is a cornerstone of OIC treatment.
  • Targeting peripheral μ-opioid receptors offers a novel therapeutic approach for OIC.